t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib

Drug resistance is a major barrier to successful cancer treatment. For patients with HER2-positive breast cancer who initially respond to therapy, the majority develop resistance within one year of treatment. Patient outcomes could improve significantly if we can find and exploit common mechanisms o...

Descripción completa

Detalles Bibliográficos
Autores principales: Christenson, Jessica L., Denny, Erin C., Kane, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741754/
https://www.ncbi.nlm.nih.gov/pubmed/26430732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741754/
https://www.ncbi.nlm.nih.gov/pubmed/26430732

Ejemplares similares